<code id='7F4D5A3BEF'></code><style id='7F4D5A3BEF'></style>
    • <acronym id='7F4D5A3BEF'></acronym>
      <center id='7F4D5A3BEF'><center id='7F4D5A3BEF'><tfoot id='7F4D5A3BEF'></tfoot></center><abbr id='7F4D5A3BEF'><dir id='7F4D5A3BEF'><tfoot id='7F4D5A3BEF'></tfoot><noframes id='7F4D5A3BEF'>

    • <optgroup id='7F4D5A3BEF'><strike id='7F4D5A3BEF'><sup id='7F4D5A3BEF'></sup></strike><code id='7F4D5A3BEF'></code></optgroup>
        1. <b id='7F4D5A3BEF'><label id='7F4D5A3BEF'><select id='7F4D5A3BEF'><dt id='7F4D5A3BEF'><span id='7F4D5A3BEF'></span></dt></select></label></b><u id='7F4D5A3BEF'></u>
          <i id='7F4D5A3BEF'><strike id='7F4D5A3BEF'><tt id='7F4D5A3BEF'><pre id='7F4D5A3BEF'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          Wikipedia

          author:comprehensive    - browse:26
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP

          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

          advertisement

          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge